
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics Inc reported a net loss of $1.14 per share for the second quarter of 2025, which was an improvement compared to the initial loss estimate of $1.22 per share, indicating a narrowing of losses and potential operational efficiency gains. The company's lead candidate, OKI-219, demonstrated favorable safety profiles across all dose levels, with no instances of hyperglycemia and only mild treatment-related adverse events reported, suggesting a strong potential for further clinical development. Overall, OnKure's focus on precision medicines targeting underserved cancer treatments and the positive data surrounding OKI-219 may position the company favorably in the competitive biopharmaceutical landscape.
Bears say
OnKure Therapeutics Inc. is projected to incur a full-year net loss of $4.56 per share for 2025, which reflects a slight improvement from a previous estimate of $4.75 per share but still indicates significant financial challenges ahead. The company faces multiple risks that could impair its financial performance, including negative clinical results with its lead asset, OKI-219, potential delays in advancing pipeline candidates, and difficulties in obtaining timely regulatory approvals. Additionally, competitive pressures from other mutant-selective PI3Kα inhibitors and the risk of long-term dilution further compound the negative outlook for the stock.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares